Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sorafenib + leuprolide + bicalutamide
- Development stage
- Discontinued
- Lead developer
- Mount Sinai Beth Israel
- Modality
- Peptides, Small Molecules
- Administration
- Oral, Intramuscular, Subcutaneous
01
Overview
This combination therapy regimen consists of the multi-kinase inhibitor sorafenib, the GnRH agonist leuprolide acetate, and the androgen receptor antagonist bicalutamide. It was specifically evaluated in a Phase I/II clinical trial (NCT00924807) led by Beth Israel Medical Center for the treatment of intermediate- and high-risk localized prostate cancer. In this therapeutic setting, sorafenib was investigated as a potential radiosensitizer to be administered concurrently with standard external beam radiotherapy and androgen deprivation therapy (ADT). Sorafenib targets multiple tyrosine kinases including VEGFR and PDGFR, as well as Raf kinases, to inhibit angiogenesis and tumor cell proliferation. Leuprolide and bicalutamide work together to achieve profound androgen suppression, which is the standard of care for hormone-sensitive prostate cancer.
- Brand names
- NexavarLupronCasodex
- Other names
- Sorafenib with ADT and Radiotherapy in Localized Prostate Cancer
02
Targets
VEGFR2 (Vascular endothelial growth factor receptor 2)GnRHR (Gonadotropin-releasing hormone receptor)BRAF (B-Raf proto-oncogene, serine/threonine kinase)PDGFRB (Platelet-derived growth factor receptor beta)KIT (c-KIT proto-oncogene receptor tyrosine kinase)RAF1 (c-Raf-1 (Y340D/Y341D))AR (Adrenergic receptors)VEGFR3 (Vascular endothelial growth factor receptor 3)VEGFR-1 (Vascular endothelial growth factor receptor 1)FLT3 (Fms related receptor tyrosine kinase 3)
Beyond the preview
Go deeper on sorafenib + leuprolide + bicalutamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sorafenib + leuprolide + bicalutamide.